HomeCompareIPCIF vs CL

IPCIF vs CL: Dividend Comparison 2026

IPCIF yields 1333.33% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPCIF wins by $241528700.57M in total portfolio value
10 years
IPCIF
IPCIF
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full IPCIF calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — IPCIF vs CL

📍 IPCIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPCIFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPCIF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPCIF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPCIF
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, IPCIF beats the other by $178,904,481,056,953.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPCIF + CL for your $10,000?

IPCIF: 50%CL: 50%
100% CL50/50100% IPCIF
Portfolio after 10yr
$120764350.32M
Annual income
$105,237,930,038,904.27/yr
Blended yield
87.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

IPCIF
No analyst data
Altman Z
-111.3
Piotroski
4/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPCIF buys
0
CL buys
0
No recent congressional trades found for IPCIF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPCIFCL
Forward yield1333.33%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$241528700.61M$40.8K
Annual income after 10y$210,475,860,072,406.56$5,401.96
Total dividends collected$239239876.27M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IPCIF vs CL ($10,000, DRIP)

YearIPCIF PortfolioIPCIF Income/yrCL PortfolioCL Income/yrGap
1← crossover$144,033$133,333.33$11,012$312.01+$133.0KIPCIF
2$1,948,924$1,794,807.89$12,196$412.95+$1.94MIPCIF
3$24,782,219$22,696,870.86$13,599$549.66+$24.77MIPCIF
4$296,245,945$269,728,970.81$15,288$736.64+$296.23MIPCIF
5$3,330,378,004$3,013,394,842.54$17,353$995.28+$3330.36MIPCIF
6$35,223,684,321$31,660,179,856.69$19,926$1,357.80+$35223.66MIPCIF
7$350,636,384,108$312,947,041,885.16$23,194$1,873.82+$350636.36MIPCIF
8$3,286,630,500,315$2,911,449,569,318.85$27,439$2,621.52+$3286630.47MIPCIF
9$29,021,346,295,663$25,504,651,660,325.88$33,088$3,727.38+$29021346.26MIPCIF
10$241,528,700,608,766$210,475,860,072,406.56$40,806$5,401.96+$241528700.57MIPCIF

IPCIF vs CL: Complete Analysis 2026

IPCIFStock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Full IPCIF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this IPCIF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPCIF vs SCHDIPCIF vs JEPIIPCIF vs OIPCIF vs KOIPCIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.